Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

Biotechnology

Healthcare
$1.98 +2.84%

+$0.11 today

Market cap
$167.23M
Beta
0.97
P/E (TTM)
-5.5
EPS (TTM)
-$0.70
52W Low $1.35High $4.60

Volume 1.04M

Average 1.37M

Returns on capital

Eledon Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-56.3%

avg -217.2%

ROIC

-55.1%

avg -71.6%

ROA

-27.0%

avg -71.9%

Analysis

ROA is currently the strongest return metric at -27.0% versus its period average of -71.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

David-Alexandre C. Gros

Chief Executive Officer & Non Independent DirectorUSD 984.41K54168.66K0.28%

Steven N. Perrin

President, Chief Scientific Officer & Non Independent DirectorUSD 792.16K60——

Paul Sean Little

Chief Financial OfficerUSD 717.38K6175.00K0.13%

Bryan E. Smith

General Counsel, Corporate Secretary & Chief Compliance OfficerUSD 377.14K4664.50K0.11%

David Hovland

Chief Regulatory Officer————

Sepideh Habibi

VP and Head of Safety & Pharmacovigilance————

John Herberger

Vice President of Technical Operations————

Marina Escudero

Vice President & Head of Clinical Operations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 31, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Eledon Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ELDN's management, answered from reported figures.

Who manages ELDN?

Eledon Pharmaceuticals, Inc. (ELDN) lists 8 active executives. The top listed executive is David Hovland, Chief Regulatory Officer.

Are ELDN insiders buying or selling?

Recent insider activity shows net buying of $69.66M.